This Pre-Solicitation opportunity from Department Of Veterans Affairs was posted on September 14, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Philadelphia VA Medical Center Radiopharmacueticals

Closed

36C24426Q0961_1Federal

Submission Closed09/21/2026, 07:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

DIBBS

Supply of Docusate Sodium Capsules

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Oral Rehydration Powder Supplier

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Dibucaine Ointment Formulation and FillingThis subcontract through the Department of Defense Medical Supply Chain Pharm FSA involves the manufacture and packaging of Dibucaine Ointment, USP, to support prime contractors fulfilling DLA medical supply contracts. The scope of work requires the formulation of an ointment containing 1% Dibucaine active ingredient, which must be filled into 1 oz / 28g collapsible tubes equipped with rectal applicators. To ensure product quality and safety, the finished units must maintain a 36-month shelf life. Compliance is a critical component of this agreement, requiring the provider to maintain FDA registration and strictly adhere to current Good Manufacturing Practices and USP standards. The opportunity is categorized under NAICS code 325412, with a response deadline set for November 9, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

DOCUSATE SODIUM CAPSUL

Solicitation # SPE2DP-27-T-0217

Solicitation SPE2DP-27-T-0217 is a request for quotations issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the procurement of Docusate Sodium Capsules, USP. The requirement consists of three packages, with each package containing 100 unit doses of 10 mg capsules. This FDA-regulated, prescription-only medication must be stored at controlled room temperature between 20 and 25 degrees Celsius and is subject to a non-extendable shelf-life requirement of 36 months. Delivery is required within 20 days after receipt of order, with the destinational point of delivery and acceptance located in Shreveport, Louisiana. The contract mandates strict adherence to quality and packaging standards, including MIL-STD-2073-1E and Medical Marking Standard No. 1. Offerors must provide manufacturer details, including the name and part number, and comply with various federal regulations such as the Buy American Act and DFARS cybersecurity reporting requirements. Invoicing and payment are to be processed electronically via the Wide Area WorkFlow system. The solicitation is open for responses until November 9, 2026, and includes preferences for HUBZone concerns while explicitly prohibiting the use of additive manufacturing for the supplied items.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

CITALOPRAM HYDROBROMID

Solicitation # SPE2DP-27-T-0218

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Solicitation # SPE2DP-27-T-0224

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Solicitation # SPE2DP-27-T-0219

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Solicitation # SPE2DP-27-T-0214

Solicitation SPE2DP-27-T-0214 is a small business set-aside issued by the DLA Troop Support Medical Supply Chain Pharm FSA for the procurement of Dibucaine Ointment, USP. The product contains 1 percent dibucaine ointment as the active ingredient and must be supplied in a collapsible tube with a rectal applicator. Each unit of issue consists of a 1 ounce or 28 gram package. The medication is FDA regulated and requires storage between 15 to 30 degrees Celsius (59 to 86 degrees Fahrenheit). The requirement specifies a non-extendable shelf life of 36 months for this Type I (Code Q) item. The contract requires delivery FOB destination to a facility in Poland by November 3, 2026, with a delivery window of 5 days after order. Packaging and marking must comply with MIL-STD-2073-1E, special packaging instructions MPPWN00001, and Medical Marking Standard No. 1. Inspection and acceptance will occur at the destination per FAR 52.246-2. The procurement is governed by various FAR and DFARS clauses, including the Buy American Act, safeguarding of covered defense information, and hazardous material identification. Quotations are due by November 9, 2026, and the award may be processed via automated award with a preference for HUBZone concerns.

Defense Logistics Agency

POSTED

DEADLINE

Solicitation # SPE2DP-27-T-0215

This solicitation, issued by the Department of Defense Medical Supply Chain Pharma FSA, is for the procurement of 7 bottles of 99% Isopropyl Alcohol (NSN 6505-00-205-6513). Each bottle must contain 473 milliliters (1 pint/16 ounces) of USP over-the-counter grade rubbing alcohol with a non-extendable shelf life of 24 months. The product is classified as a highly flammable liquid and must be stored at controlled room temperatures between 20°C and 25°C. Delivery is required within 20 days after order, with the destination point located in Jacksonville, Florida. Due to the hazardous nature of the material, the contractor must provide a current Material Safety Data Sheet (MSDS) and ensure all packaging and labeling comply with 49 CFR, 29 CFR, and ICAO or IMDG Annex 1 standards. Marking must strictly adhere to Medical Marking Standard No. 1, which supersedes MIL-STD-129. The contract incorporates several federal regulations, including the Buy American and Balance of Payments Program (DFARS 252.225-7001) and destination inspection requirements under FAR 52.246-2. Invoicing and receiving reports must be processed electronically through the Wide Area WorkFlow (WAWF) system.

Defense Logistics Agency

POSTED

DEADLINE

RINGER'S INJECTION, LAC

Solicitation # SPE2DP-27-T-0222

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

HYDROGEN PEROXIDE TOPI

Solicitation # SPE2DP-27-T-0216

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

6505--Request for Information (RFI) - Specialty Pharmacy â€“ Pharmaceutical Prime Vendor (PPV) 2028

Solicitation # 36E79727Q0001

The Department of Veterans Affairs, through the OALC Enterprise Procurement Office, has issued a Request for Information regarding the Pharmaceutical Prime Vendor (PPV) 2028 program. The agency is seeking market research to determine the feasibility of integrating Limited Distribution and Closed Distribution Products (CDP) into the PPV scope. These specialty medications are typically high-cost, low-volume items with restricted distribution channels that often require specific clinical justifications, manufacturer-mandated registrations, and specialized safety monitoring. The primary objective is to establish a seamless ordering platform where all Federal Supply Schedule (FSS) items, including those that bypass the physical possession of the prime vendor, are visible and orderable with accurate invoicing and delivery tracking for VA medical centers nationwide. The government is soliciting detailed feedback from industry partners on their ability to coordinate fulfillment with manufacturer-designated specialty distributors and their capacity to provide consistent reporting and reconciliation for these transactions. Potential respondents must provide their company name, point of contact information, UEI, CAGE code, and any applicable socioeconomic designations. Submissions are due by 11 AM Central on November 16, 2026, via email to Karen Ade. This notice is strictly for market research purposes and does not constitute a formal solicitation or a commitment by the government to award a contract.

Nac Prime Vendor (36W797)

POSTED

about 15 hours ago

DEADLINE

in 14 days

AI Contract Overview

The Department of Veterans Affairs, through Network Contract Office 4, is seeking a licensed and Nuclear Regulatory Commission accredited vendor to supply essential radiopharmaceuticals and calibration sources for the Nuclear Medicine Department at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia, Pennsylvania. These materials are critical for maintaining equipment quality control and performing necessary imaging procedures. The requirement is categorized under NAICS code 325412 and is designated as an SBA set-aside. The procurement process is identified by solicitation number 36C24426Q0961_1, with a response deadline of September 21, 2026. The resulting contract is intended to include a base period with four additional option years to ensure a consistent supply of medical materials. Keri Hester serves as the primary point of contact for this effort, which is managed by the office located in Pittsburgh, Pennsylvania.

General Info

VA seeks accredited vendor for radiopharmaceuticals and calibration sources in Philadelphia, PA.

Agency

Department Of Veterans Affairs → 244-NETWORK Contract Office 4 (36C244)

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

PA, 19104, USA

Set-Aside

NONE

Documents

2 pages · presolicitation

Low

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedSep 14

Presolicitation

Response DeadlineSep 21

Deadline has passed

Submission Closed

09/21/2026, 07:00:00 PM UTC

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Veterans Affairs → 244-NETWORK Contract Office 4 (36C244)

Contacts1 person available

OfficePITTSBURGH, PA, 15215, USA

Organization / AgencyDepartment Of Veterans Affairs → 244-NETWORK Contract Office 4 (36C244)

Office AddressPITTSBURGH, PA, 15215, USA

Contacts

Keri Hester

contact@example.gov

+1 (555) 000-0000

Full Description

The Corporal Michael J. Crescenz VA Medical Center (CMCVAMC) is seeking a licensed vendor, accredited by the Nuclear Regulatory Commission, to provide essential radiopharmaceuticals and calibration sources for its Nuclear Medicine Department to include 4 option years. These supplies are critical for performing imaging procedures and ensuring equipment quality control.